|
Legislative Task Force Releases Findings on Regulating Psychedelic Medicines
JUNEAU, AK — Today, the Alaska Legislative Task Force for the Regulation of Psychedelic Medicines released its final report, which provides policy recommendations in preparation for potential future federal approval of psychedelic medicines. This report reflects months of deliberation, public input, and expert analysis. The Task Force was created in the 33rd Alaska State Legislature through House Bill 228.
The Task Force met over the course of the 2025 legislative session to assess the state’s readiness for the possibility of psychedelic-based therapies being approved by the U.S. Food and Drug Administration (FDA). The Task Force focused on four main goals: Assessing the potential role of psychedelic medicine in mental health treatment, identifying barriers to implementation and equitable access, formulating licensing and insurance requirements for healthcare practitioners, and exploring legal and regulatory frameworks for the legalization and public health implications of psychedelic medicines.
“Alaska has some of the highest rates in the nation of domestic violence survivors and combat veterans who experience PTSD, and many of these Alaskans continue to struggle with traditional treatments,” said Co-Chair Senator Forrest Dunbar, D-Anchorage. “Our approach to these new medical therapies needs to be properly and independently evaluated to ensure that if the legislature were to make policy changes, we do so with empirical data in a properly controlled environment.”
The Task Force concluded that psychedelic medicines may benefit veterans, survivors of violence, and individuals with treatment-resistant PTSD through structured clinical settings as part of clinical therapy. The Task Force emphasized the critical importance of strong informed consent, including clear education, defined boundaries, and explicit agreement with patients on treatment practices. Additionally, the Task Force issued 26 policy recommendations for this and future legislatures to consider.
“This task force focused on preparing Alaska for potential federal approval of psychedelic therapies,” said Co-Chair Representative Justin Ruffridge, R-Soldotna. “These recommendations came from months of collaboration and work by medical professionals, advocates, and legislators who focused on patient safety, evidence-based care, and access, especially for those who haven’t seen progress through traditional treatments.”
On a national scale, ongoing clinical research on the therapeutic use of psychedelics such as LSD, psilocybin, and MDMA for anxiety, addiction, and PTSD has shown positive outcomes, leading to advances in medical education, research, and public policy.
In addition, the U.S. Department of Veterans Affairs is currently funding research on psychedelics, such as MDMA and psilocybin, to treat PTSD and depression among veterans, marking the first exploration of these compounds' medical benefits since the 1960s. The move follows the Federal Drug Administration’s application of “breakthrough status,” which allows accelerated clinical trials and, in turn, has increased interest among veterans, researchers, and lawmakers.
You can read the full Legislative Task Force report here.
###
| 
